Literature DB >> 17060589

Parkinsonism, Lrrk2 G2019S, and tau neuropathology.

A Rajput1, D W Dickson, C A Robinson, O A Ross, J C Dächsel, S J Lincoln, S A Cobb, M L Rajput, M J Farrer.   

Abstract

Lrrk2 G2019S is predominantly associated with alpha-synuclein-immunopositive Lewy body pathology. We have identified Family SK where Lrrk2 G2019S segregates with slowly progressive parkinsonism and the affected proband has tau-immunopositive neurofibrillary tangle pathology. Thus alpha-synucleinopathy and tauopathy, the predominant pathologies associated with parkinsonism, may be alternate outcomes of the same underlying genetic cause. Intriguingly, we observe no evidence of a direct interaction between either the tau or alpha-synuclein protein with Lrrk2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17060589     DOI: 10.1212/01.wnl.0000240220.33950.0c

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  87 in total

Review 1.  Genetic mouse models for understanding LRRK2 biology, pathology and pre-clinical application.

Authors:  Zhenyu Yue
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

2.  Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease.

Authors:  Fabio Di Domenico; Rukhsana Sultana; Andrew Ferree; Katelyn Smith; Eugenio Barone; Marzia Perluigi; Raffaella Coccia; William Pierce; Jian Cai; Cesare Mancuso; Rachel Squillace; Manfred Wiengele; Isabella Dalle-Donne; Benjamin Wolozin; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2012-03-20       Impact factor: 8.401

3.  (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Authors:  C-Y Chen; Y-H Weng; K-Y Chien; K-J Lin; T-H Yeh; Y-P Cheng; C-S Lu; H-L Wang
Journal:  Cell Death Differ       Date:  2012-04-27       Impact factor: 15.828

4.  Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes.

Authors:  Kazuko Hasegawa; A Jon Stoessl; Teruo Yokoyama; Hisayuki Kowa; Zbigniew K Wszolek; Saburo Yagishita
Journal:  Parkinsonism Relat Disord       Date:  2008-09-18       Impact factor: 4.891

Review 5.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

6.  Evidence for a common pathway linking neurodegenerative diseases.

Authors:  Joshua M Shulman; Philip L De Jager
Journal:  Nat Genet       Date:  2009-12       Impact factor: 38.330

7.  G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.

Authors:  Carles Gaig; María José Martí; Mario Ezquerra; Adriana Cardozo; Maria Jesus Rey; Eduardo Tolosa
Journal:  BMJ Case Rep       Date:  2009-01-23

Review 8.  Role of LRRK2 kinase dysfunction in Parkinson disease.

Authors:  Azad Kumar; Mark R Cookson
Journal:  Expert Rev Mol Med       Date:  2011-06-13       Impact factor: 5.600

Review 9.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

10.  Genetic Modifiers of Neurodegeneration in a Drosophila Model of Parkinson's Disease.

Authors:  Sierra Lavoy; Vinita G Chittoor-Vinod; Clement Y Chow; Ian Martin
Journal:  Genetics       Date:  2018-06-15       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.